Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Open accessThe DOI matches its Crossref record; 187 of the 187 references it cites were found in a registry or an index.
Abstract
Mood disorders are common, chronic, recurrent mental illnesses that affect the lives of millions of individuals worldwide. To date, the monoaminergic systems (serotonergic, noradrenergic and dopaminergic) in the brain have received the greatest attention in neurobiological studies of mood disorders, and most therapeutics target these systems. However, there is growing evidence that the glutamatergic system is central to the neurobiology and treatment of these disorders. Here, we review data supporting the involvement of the glutamatergic system in mood-disorder pathophysiology as well as the efficacy of glutamatergic agents in mood disorders. We also discuss exciting new prospects for the development of improved therapeutics for these devastating disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This could lead to astrocyte/microglia imbalance, glutamatergic overproduction and excitotoxic neuronal damage (Sanacora et al., 2008) with impact on synapse functionality.”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Sanacora et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, increased glutamate levels has been associated with mechanisms involved in stress and depression, such as neuro-inflammatory process, decreased levels of neurotrophic factors, diminished neurogenesis, and neuroplasticity impairment [116,117].”
From P2X7 Receptor Signaling in Stress and Depression (2019) · cites this paper as [117]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, rapidly acting antidepressants were discovered in the glutamatergic system (Berman et al., 2000;Sanacora et al., 2008).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Sanacora et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“Several classes of antidepressants as well as SSRIs are known to exert action on the glutamate system by influencing NMDA or AMPA receptor transcription (Sanacora et al., 2008).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Sanacora et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“Glia also play an important role in regulating the synthesis and reuptake of glutamate and thereby influence synaptic function and morphology16,17.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“Although most patients with mood disorders receive some benefit from available treatment”
BackgroundTrivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Self-citationA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationEvidence-based health policy—lessons from the Global Burden of Disease Study
Murray, C. J. L., & Lopez, A. D. (1996) · Science · doi:10.1126/science.274.5288.740 · Cited by 2,178
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043 · cited 1×
“, and is approved for the treatment of moderate to severe Alzheimer's disease, in which it has been shown to enhance cognition and minimize clinical deterioration in patients with Alzheimer's disease, vascular dementia or mixed dementi”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Research works printed but not linked: 1
- Preskorn, S. et al. A placebo-controlled trial of the NR2B subunit specific NMDA antagonist CP-101,606 plus paroxetine for treatment resistant depression (TRD). Annual Conference of the American Psychological Association (San Francisco, California) 154 (2007).
Cited by
Items 701–800 of 1,000
Yoshida, M., Katada, H., Isozumi, Y., Suzuki, C., Yoshimi, A., Ozaki, N., & Noda, Y. (2024) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2024.12.007 · Cited by 4
The Compulsive Obsessive Disorder: many clues, still little evidence
Maraone, A., Panfili, M., Wilson Jones, G., Pinucci, I., Biondi, M., & Pasquini, M. (2024) · Giornale italiano di psicopatologia/Journal of psychopathology/Italian journal of psychopathology · doi:10.36148/2284-0249-n452 · Cited by 4
Quiroz, J. A., Chen, G., Drevets, W. C., Henter, I. D., & Manji, H. K. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511980053.004 · Cited by 4
Self-citationThe Potential Role of the Endogenous Opioid System in the Antidepressant Effect of Ketamine
Shenoda, B. B. (2014) · Research in Neurology An International Journal · doi:10.5171/2014.733320 · Cited by 4
Hashimoto, K. (2017) · Neuromethods · doi:10.1007/978-1-4939-7228-9_16 · Cited by 4
Ketamine in treatment-resistant depression
Lapidus, K. A. B., & Mathew, S. J. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139175869.027 · Cited by 4
Multifunctional antistress effects of standardized aqueous extracts fromHippophae rhamnoidesL.
Bae, D., Kim, J., Oh, D.-R., Kim, Y., Choi, E.-J., Lee, H., Jung, M., Lee, S. Y., Jeong, C., Lee, M., et al. (2016) · Animal Cells and Systems · doi:10.1080/19768354.2016.1250816 · Cited by 4
Zhu, L., Chang, L., Shi, H., & Li, N. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.12.037 · Cited by 4
Involvement of PKCβI-SERT activity in stress vulnerability of mice exposed to twice-swim stress
Ito, T., Hiramatsu, Y., Mouri, A., Yoshigai, T., Takahashi, A., Yoshimi, A., Mamiya, T., Ozaki, N., & Noda, Y. (2021) · Neuroscience Research · doi:10.1016/j.neures.2021.01.002 · Cited by 4
Neurotransmitter Systems in Bipolar Disorder
Nakic, M., Krystal, J. H., & Bhagwagar, Z. (2010) · Wiley eBooks · doi:10.1002/9780470661277.ch16 · Cited by 4
Self-citationNeurodegenerative changes in depression: Excitotoxicity or a deficit of trophic factors?
Kudryashova, I. V. (2015) · Neurochemical Journal · doi:10.1134/s1819712415010043 · Cited by 4
Triple‐Uptake Inhibitors (Broad‐Spectrum Antidepressants)
Skolnick, P. (2012) · Wiley eBooks · doi:10.1002/9781118098141.ch18 · Cited by 4
Antidepressant-Like Effects of Ketamine on Fear Conditioning and Extinction
Kulyk, B. D. (2017) · University Library - University of Saskatchewan (University of Saskatchewan) · Cited by 4
Pasquini, M., Brakoulias, V., & Pallanti, S. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00093 · Cited by 4
Pavlova, T. A., Telepina, M. A., Perelygin, V. V., Smetannikova, E. A., Sklyarova, N. A., & Orlova, A. V. (2025) · Pharmacy Formulas · doi:10.17816/phf686915 · Cited by 3
Kim, S. E., Joo, Y., Son, Y., Kim, H.-K., Lee, S., Lee, M., Ido, T., & Kim, J. (2020) · Brain Structure and Function · doi:10.1007/s00429-020-02094-7 · Cited by 3
O'Shea, M. J., Anversa, R. G., Ch’ng, S. S., Campbell, E. J., Walker, L. C., Andrews, Z. B., Lawrence, A. J., & Brown, R. M. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116637 · Cited by 3
Shen, Y., Wei, R., Liu, D., Lv, F., Ren, L., & Min, S. (2025) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2025.173955 · Cited by 3
Overcoming Antidepressant Treatment Resistance: Focus on Glutamate
Murrough, J. W., & Mathew, S. J. (2010) · Modern trends in psychiatry · doi:10.1159/000319509 · Cited by 3
Shallie, P. D., Sulaiman, A. I., Oladejo, M. K., Shallie, O. F., & Naicker, T. (2021) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2021.02.003 · Cited by 3
Kosuge, A., Kunisawa, K., Iida, T., Wulaer, B., Kawai, T., Tanabe, M., Saito, K., Nabeshima, T., & Mouri, A. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16100 · Cited by 3
Dong, H., Luo, T., Yang, C., Liu, M., Shen, Y., & Hao, W. (2024) · Schizophrenia · doi:10.1038/s41537-024-00506-9 · Cited by 3
Meng, W., Yang, Q., Xu, J., Huang, Y., Wang, C., Song, Q., Song, L., Bian, J., Ma, Q., Ma, A., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106391 · Cited by 3
Mischel, N., Kritzer, M. D., Patkar, A. A., Masand, P. S., & Szabo, S. T. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001132 · Cited by 3
Biological Mechanisms of Psychosomatic Symptoms
Baloh, R. W. (2020) · Springer eBooks · doi:10.1007/978-3-030-59181-6_5 · Cited by 3
Anxiety and depression: leading edge of therapy
Mathew, S. J., & Charney, D. S. (2008) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20049 · Cited by 3
Antidepressant-like Effects of the Gastrodia elata Bl Extract in Mice
Hong, S.-S., & Cho, S. (2013) · Journal of Oriental Neuropsychiatry · doi:10.7231/jon.2013.24.3.281 · Cited by 3
Depressive Disorders: Prevalence, Costs, and Theories
Grosso, C., Valentão, P., & Andrade, P. B. (2016) · Springer eBooks · doi:10.1007/978-3-319-14021-6_1 · Cited by 3
Role of glutamate transporters in the pathophysiology of major mental illnesses
Tanaka, K. (2013) · Folia Pharmacologica Japonica · doi:10.1254/fpj.142.291 · Cited by 3
Twohig, P. A., & Huckfeldt, V. (2016) · International Journal of Medical Students · doi:10.5195/ijms.2016.153 · Cited by 3
Glutamate NMDA receptor modulators for the treatment of depression: trials and tribulations
Murrough, J. W. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3888-z · Cited by 3
NR2B antagonist pursued for treatment-resistant depression
(2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2880 · Cited by 3
Therapeutic doses of ketamine acutely attenuate the aversive effect of losses during decision-making
Oemisch, M., & Seo, H. (2023) · eLife · doi:10.7554/elife.87529 · Cited by 2
Zhang, W., Jiang, G., Kang, H., Wang, J., Liu, Z., Wang, Z., Huang, D., & Gao, A. (2024) · Environment & Health · doi:10.1021/envhealth.4c00186 · Cited by 2
Song, C.-M., Liu, J., Yang, H., Li, Q., Wang, S., Chen, H. I., Wang, S.-F., Chen, L., Gu, S., Zhang, F., et al. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1630294 · Cited by 2
Chen, Y., Guo, L., Zan, G., Xu, C., Yao, S.-Y., Wu, S., Jiang, X., Liu, Z., Long, J.-D., Liu, B., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03441-y · Cited by 2
Song, H., Bang, D., Koo, B., Kim, S., & Lee, S. (2026) · Briefings in Bioinformatics · doi:10.1093/bib/bbag472 · Cited by 2
Kuan, P. F., Mann, F. D., Yang, X., Kotov, R., Clouston, S., Ilkayeva, O., Muehlbauer, M. J., Newgard, C. B., & Luft, B. J. (2026) · Nature Communications · doi:10.1038/s41467-026-74757-8 · Cited by 2
Metabotropic Glutamate Receptors in Anxiety Disorder
Xu, J., & Zhu, Y. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002630 · Cited by 2
Novel Targets for Drug Treatment in Psychiatry
Kurita, M., García‐Bea, A., & González‐Maeso, J. (2016) · Springer eBooks · doi:10.1007/978-1-4939-2528-5_30 · Cited by 2
The Role of mTOR in Mood Disorders Pathophysiology and Treatment
Réus, G. Z., Pitcher, M. R., Arent, C. O., & Quevedo, J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802733-2.00015-3 · Cited by 2
Pharmacology of Anesthetic Drugs Used in Out of Operating Room Anesthesia
Duggan, E. W., & Schwock, K. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-39150-2_2 · Cited by 2
Zhou, J., Bao, Q., Liang, S., Guo, H. Y., Meng, X., Zhang, G., & Li, P. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10210 · Cited by 2
Sahraei, M., Sahraei, H., Rahimi, M., Khosravi, M., Ganjkhani, M., & Meftahi, G. H. (2021) · Journal of Complementary and Integrative Medicine · doi:10.1515/jcim-2021-0159 · Cited by 2
The Modulation of Glutamatergic Signaling as a Potential Therapeutic Strategy for Major Depression
Molero, P., Aubá, E., Unceta, M. D. M., & Pedreño, F. O. S. (2022) · Springer eBooks · doi:10.1007/978-3-030-87480-3_11 · Cited by 2
Rodrigues, K. D. C., Oliveira, M. D. C., dos Santos, B. F., Domingues, N. L. C., Fronza, M. G., Savegnago, L., Wilhelm, E. A., & Luchese, C. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06647-0 · Cited by 2
Neurobiological Augmentation of Psychotherapy in Treatment Resistant Depression
Li, S. (2014) · Journal of Depression & Anxiety · doi:10.4172/2167-1044.s2-002 · Cited by 2
Neurochemical and Metabolic Imaging in Bipolar Disorder
Kim, J. E., Lyoo, I. K., & Renshaw, P. F. (2012) · Oxford University Press eBooks · doi:10.1093/med/9780199797608.003.0039 · Cited by 2
Lepow, L., Luckenbaugh, D. A., Park, L., Henter, I. D., & Zarate, C. A. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.10.023 · Cited by 2
Self-citationAgomelatin ve etki mekanizması
Karamustafalıoğlu, O., & Baran, E. (2012) · Journal of Mood Disorders · doi:10.5455/jmood.20120922232245 · Cited by 2
Depression, Sleep Disorders, and DA
Speed, T. J., & Finan, P. H. (2016) · Springer eBooks · doi:10.1007/978-3-319-46437-4_9 · Cited by 2
Structural and Neurochemical Alterations in Brain Regions of Depression and Suicide Patients
Basak, A. K., & Chatterjee, T. (2016) · Clinical Depression · doi:10.4172/2572-0791.1000117 · Cited by 2
Meeting Emerging Challenges and Opportunities in Psychiatry Through Computational Neuroscience
Anticevic, A., Krystal, J. H., & Murray, J. D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809825-7.02004-6 · Cited by 2
Self-citationCoplan, J. D., Gupta, N. K., Flynn, S. K., Reiner, W. J., Gaita, D. J., Fulton, S. L., Rozenboym, A. V., Tang, J. E., Cooper, T. B., & Mann, J. J. (2018) · Chronic Stress · doi:10.1177/2470547018785625 · Cited by 2
Dysregulation of the Glutamatergic System in Major Depressive Disorder
Cooper, T. M., & Iosifescu, D. V. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-58131-8.00012-4 · Cited by 2
Neurotransmitter Release of Reprogrammed Cells Using Electrochemical Detection Methods
Heuer, A. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1601-7_14 · Cited by 2
Schmerder, K., & Freund, N. (2022) · Neuromethods · doi:10.1007/978-1-0716-2748-8_13 · Cited by 2
N-Methyl-d-Aspartate (NMDA) Antagonists for the Treatment of Depression
Skolnick, P., Popik, P., & Trullás, R. (2010) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0346-0241-9_1 · Cited by 2
Reply to Comments on "Optimizing Early Prediction for Antipsychotic Response in Schizophrenia"
Chang, Y., & Lane, H. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181ad3226 · Cited by 2
Favre-Besse, F.-C. (2012) · theses.fr (ABES) · doi:10.70675/5bb71069z5b5az4767zaea3zf859650fb47d · Cited by 2
Obiero, G. F. (2014) · UWC Research Repository (University of the Western Cape) · Cited by 2
Ketamine’s fast antidepressant drug response: Biosignatures and pathways
Weckmann, K. (2017) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.21639 · Cited by 2
The Affective Disorder Test: a new test to assess depression and anxiety-like behaviour in rats
Blackburne, K. (2021) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.16840765.v1 · Cited by 2
The effects of sildenafil on neuroplasticity in human neuroblastoma cells
Reay, R. (2010) · Boloka Institutional Repository (North-west University) · Cited by 2
Visser, G. P. (2012) · Boloka Institutional Repository (North-west University) · Cited by 2
Paz, V. (2018) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 2
Anxiety and Anguish - Psychological Explorations and Anthropological Figures
Irtelli, F., & Gabrielli, F. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.111112 · Cited by 1
Quchani, M. R., Farmanesh, E., Esmaili, A., Moghimi, A., Fereidoni, M., & Rahati, S. (2023) · Toxicon · doi:10.1016/j.toxicon.2023.107233 · Cited by 1
Rezgui, R., Alharazi, T. H., Alshaghdali, K., Elnaem, I. S., Salih, M. A. I., Aldakheel, F., Saeed, M., Tasleem, M., Ginawi, I., & Saeed, A. (2024) · Pharmacognosy Magazine · doi:10.1177/09731296241294132 · Cited by 1
Liao, Y., Zhou, K., Guo, Z., Lu, Q., Deng, S., Yang, H. B., Weng, B., & Pan, L. (2025) · Scientific Reports · doi:10.1038/s41598-024-85047-y · Cited by 1
The impact of psychiatric comorbidities on the survival of cancer patients
-, G. D., Ciobica, A. S., & Dobrin, I. (2025) · Bulletin of Integrative Psychiatry · doi:10.36219/bpi.2025.1.09 · Cited by 1
Clinical and neurobiological effects of creatine supplementation in depressive disorders
dos Santos, M. G., & BITTENCOURT, Y. D. (2025) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2025.26.2.2095 · Cited by 1
Yang, X., Cui, Y., He, Z., Xu, J., Chen, T., Liu, S., Wang, L., & Zhang, S. (2025) · Arabian Journal of Chemistry · doi:10.25259/ajc_89_2025 · Cited by 1
Neurobiological mechanisms and recent advances in drug-based therapeutics in depression
Ahmadnia, H., Abdollahzadeh, R., Hatami, H., Masoumi, S., Moezzi, S. M. I., Shahsavari, K., Khanavi, M., Yazarlu, O., Majd, M. T., & Hasanpour, M. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.11.002 · Cited by 1
Olivo, D., Miola, A., Comini, F. F., Trevisan, N., Librizzi, G., Toffanin, T., Manara, R., & Sambataro, F. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.11.015 · Cited by 1
Carmellini, P., Cuomo, A., Rescalli, M. B., Pinzi, M., Dourmas, A., & Fagiolini, A. M. (2026) · Pharmaceuticals · doi:10.3390/ph19050662 · Cited by 1
Mansari, M. E., Okamoto, N., & Blier, P. (2026) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyag020 · Cited by 1
Depression in neurodegenerative disease: neurobiological mechanisms and emerging treatments
Costello, H., Reeves, S., Glue, P., Young, A. H., & Howard, R. J. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03728-8 · Cited by 1
Novel Therapeutic Strategies for Bipolar Disorder
Machado‐Vieira, R., Manji, H. K., & Zarate, C. A. (2010) · Wiley eBooks · doi:10.1002/9780470661277.ch30 · Cited by 1
Self-citationNovel Therapeutic Approaches for Treating Bipolar Disorder
Machado‐Vieira, R., Henter, I. D., Baumann, J., Latov, D. R., Wheeler‐Castillo, C., & Zarate, C. A. (2011) · Wiley eBooks · doi:10.1002/9780470975114.ch21 · Cited by 1
Self-citationVanvossen, A. C. (2012) · Cited by 1
Potential novel treatments for bipolar depression
Zarate, C. A., & Manji, H. K. (2009) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8567-5_12 · Cited by 1
Self-citationKetamin: Yeni Bir Antidepresan? Ketamine: A New Antidepressant?
Karacaer, F. (2015) · Cited by 1
Improving effects of chotosan on the brain malfunction in rodent’s disease models
Oka, J., Matsumoto, K., & Sasaki‐Hamada, S. (2016) · Folia Pharmacologica Japonica · doi:10.1254/fpj.147.157 · Cited by 1
Ketamine’s Mechanisms of Rapid Antidepressant Activity: Evidence from Preclinical Studies
Hermes, G., & Sanacora, G. (2016) · Springer eBooks · doi:10.1007/978-3-319-42925-0_6 · Cited by 1
Self-citationAntidépresseurs : aspects pharmacologiques
Gauthier, C., Souaiby, L., Poirier, M., Olié, J., Krebs, M., & Gaillard, R. (2016) · Time to knit · doi:10.1016/s0246-1072(16)75754-3 · Cited by 1
Novel Therapeutics in Bipolar Disorder
da Costa, S. C., Machado‐Vieira, R., & Soares, J. C. (2018) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-018-0140-6 · Cited by 1
Brain PET Poster Sessions PP01-M01 to PP02-N07
Lange, D., Tejada, I. M., xiong, M., Hillebrand, B., Noergaard, M., Baerentzen, S., Shalgunov, V., Herth, M. M., Svarer, C., & Palner, M. (2019) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19851018 · Cited by 1
AMPA Receptor Potentiators as Potential Rapid-Acting Antidepressants
Garro-Martínez, E., & Adell, A. (2021) · Contemporary clinical neuroscience · doi:10.1007/978-3-030-79790-4_6 · Cited by 1
Where is the Mechanistic Target of Rapamycin Signaling Pathway in Depression?
Lee, J. A. (2022) · Mood and Emotion · doi:10.35986/me.2022.20.2.23 · Cited by 1
Psychopharmacotherapy of Depressive Disorders
Kavakbasi, E., & Baune, B. T. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_427 · Cited by 1
Bielecka‐Papierz, G., Poleszak, E., Listos, J., Szewczyk, B., Szopa, A., Orzelska‐Górka, J., Turek, J., Bederska‐Łojewska, D., Jakóbczuk, M., Szponar, J., et al. (2023) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13779 · Cited by 1
Study of Associations of the GRM8 Gene with Antipsychoticinduced Hyperprolactinemia
Poltavskaya, E. G., Владимирович, Т. В., Boiko, A. S., Kornetova, E. G., Ivanova, S. А., & Fedorenko, O. Y. (2023) · Personalized Psychiatry and Neurology · doi:10.52667/2712-9179-2023-3-1-42-47 · Cited by 1
A single dose of lamotrigine induces a positive memory bias in healthy volunteers
Zghoul, T., Artiach-Hortelano, P., Kaltenboeck, A., Wright, L., Goodwin, G., Capitão, L., & Harmer, C. (2023) · Psychological Medicine · doi:10.1017/s0033291725000777 · Cited by 1
Maksimovic, M. (2015) · Helda - University of Helsinki Institutional Repository · Cited by 1
Forms of flexibility : associations between executive functions in the rat
Chase, E. (2013) · St Andrews Research Repository (St Andrews Research Repository) · Cited by 1
Plasticity based strategies for the treatment of depression
Apazoglou, K. (2012) · theses.fr (ABES) · doi:10.70675/1ffaa907z696az4218zacbfzac7807473e37 · Cited by 1
Treatment of Lewy-body dementias and psychopathology
Marsh, L. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70208-8 · Cited by 1
Genetic studies in mood disorders
Lekman, M. (2014) · Figshare · Cited by 1
Metadata
- Authors
- Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K.
- Affiliations
- Yale University (US)
- National Institutes of Health (US)
- Corresponding author
- Manji, Husseini K.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2008-05
- Volume
- 7
- Issue
- 5
- Pages
- 426-437
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC2715836
- OpenAlex
- W2074907255
- Cited by
- 894
- References
- 186
- Citations by year
- 2026: 17 · 2025: 29 · 2024: 33 · 2023: 44 · 2022: 36 · 2021: 44 · 2020: 56 · 2019: 43 · 2018: 40 · 2017: 50 · 2016: 63 · 2015: 70 · 2014: 59 · 2013: 56 · 2012: 68
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health (K02MH076222, Z01MH002828, Z01MH002857)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- glutamatergic system, mood disorders, antidepressants, neuroplasticity, glutamatergic agents, monoaminergic systems, rapid-acting antidepressants, drug development
- MeSH terms
- Animals, Glutamates, Humans, Psychotropic Drugs, Excitatory Amino Acid Antagonists, Mood Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.